NL0010391025 - Common Stock

Taking everything into account, **PHARM** scores **3** out of 10 in our fundamental rating. **PHARM** was compared to 79 industry peers in the **Biotechnology** industry. **PHARM** may be in some trouble as it scores bad on both profitability and health. **PHARM** is quite expensive at the moment. It does show a decent growth rate.

In the past year **PHARM** has reported negative net income.

Of the past 5 years **PHARM** 4 years had a positive operating cash flow.

The profitability ratios for **PHARM** are negative, so there is not much use analyzing them.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | N/A | ||

ROE | N/A | ||

ROIC | N/A |

ROA(3y)1.65%

ROA(5y)5.8%

ROE(3y)3.38%

ROE(5y)12.69%

ROIC(3y)N/A

ROIC(5y)N/A

The **Gross Margin** of **PHARM** (**88.55%**) is better than **88.00%** of its industry peers.

In the last couple of years the **Gross Margin** of **PHARM** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 88.55% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.31%

GM growth 5Y1.43%

The number of shares outstanding for **PHARM** has been increased compared to 1 year ago.

Compared to 1 year ago, **PHARM** has an improved debt to assets ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | N/A | ||

Altman-Z | N/A |

ROIC/WACCN/A

WACC4.8%

A Current Ratio of **4.06** indicates that **PHARM** has no problem at all paying its short term obligations.

Looking at the **Current ratio**, with a value of **4.06**, **PHARM** is in the better half of the industry, outperforming **77.33%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 4.06 | ||

Quick Ratio | 3.33 |

The **Earnings Per Share** has grown by an nice **16.67%** over the past year.

Looking at the last year, **PHARM** shows a very strong growth in **Revenue**. The Revenue has grown by **34.54%**.

Measured over the past years, **PHARM** shows a quite strong growth in **Revenue**. The Revenue has been growing by **11.35%** on average per year.

EPS 1Y (TTM)16.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-190.31%

Revenue 1Y (TTM)34.54%

Revenue growth 3Y4.96%

Revenue growth 5Y11.35%

Sales Q2Q%34.97%

EPS Next Y116.09%

EPS Next 2Y95.41%

EPS Next 3Y85.29%

EPS Next 5Y58.41%

Revenue Next Year22.33%

Revenue Next 2Y18.74%

Revenue Next 3Y18.54%

Revenue Next 5Y11.77%

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

The **Price/Earnings Ratio** is negative for **PHARM**. In the last year negative earnings were reported.

Based on the **Price/Forward Earnings** ratio of **27.01**, the valuation of **PHARM** can be described as expensive.

77.33% of the companies in the same industry are more expensive than **PHARM**, based on the **Price/Forward Earnings** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 27.01 |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

A more expensive valuation may be justified as **PHARM**'s earnings are expected to grow with **85.29%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y95.41%

EPS Next 3Y85.29%

No dividends for **PHARM**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**PHARMING GROUP NV**

AMS:PHARM (8/9/2024, 7:00:00 PM)

**0.72**

**0 (-0.14%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap48.49M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 27.01 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | N/A | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 88.55% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset TurnoverN/A

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 4.06 | ||

Quick Ratio | 3.33 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)16.67%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y116.09%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)34.54%

Revenue growth 3Y4.96%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y